BioXcel Therapeutics (BTAI) Change in Receivables (2023 - 2026)
BioXcel Therapeutics' (BTAI) quarterly Change in Receivables came in at -$17000.0 in Q1 2026, up 87.02% year-on-year from -$9089.8 in Q1 2025, and down 107.3% quarter-over-quarter from $233000.0 in Q4 2025.
BioXcel Therapeutics (BTAI) Change in Receivables (2023 - 2026) Analysis & Trends
BioXcel Therapeutics' Change in Receivables history runs 4 years deep, the most recent figure standing at -$17000.0 for Q1 2026.
- On a quarterly basis, Change in Receivables rose 87.02% year-over-year to -$17000.0 in Q1 2026; TTM through Mar 2026 was $216000.0, a 157.14% increase from a year earlier, with the FY2025 full-year figure at $102000.0, up 70.0% from the prior year.
- Change in Receivables fell to -$17000.0 in Q1 2026 per BTAI's latest filing, from $233000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $434000.0 in Q2 2024 and bottomed at -$809000.0 in Q3 2024.
- The 4-year median for Change in Receivables is $35000.0 (2023), against an average of -$2461.5.
- Biggest YoY gain for Change in Receivables was 777.14% in 2024; the steepest drop was 366.12% in 2024.
- Year by year, Change in Receivables stood at -$664000.0 in 2023, then surged by 119.28% to $128000.0 in 2024, then surged by 82.03% to $233000.0 in 2025, then tumbled by 107.3% to -$17000.0 in 2026.
- Per Business Quant, the three latest BTAI Change in Receivables figures stand at -$17000.0 (Q1 2026), $233000.0 (Q4 2025), and -$17000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -78.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 106.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -621.82 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -38.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 126.30 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 81.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | BioXcel Therapeutics | 10.62 Mn | 10.62 Mn | -77,000.00 | -17,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17,000.00 |
| Mar 31, 2026 | -17,000.00 |
| Dec 31, 2025 | 233,000.00 |
| Dec 31, 2025 | 233,000.00 |
| Sep 30, 2025 | -17,000.00 |
| Sep 30, 2025 | -17,000.00 |
| Jun 30, 2025 | 17,000.00 |
| Jun 30, 2025 | 17,000.00 |
| Mar 31, 2025 | -131,000.00 |
| Mar 31, 2025 | -131,000.00 |
| Dec 31, 2024 | 128,000.00 |
| Dec 31, 2024 | 128,000.00 |
| Sep 30, 2024 | -809,000.00 |
| Sep 30, 2024 | -809,000.00 |
| Jun 30, 2024 | 434,000.00 |
| Jun 30, 2024 | 434,000.00 |
| Mar 31, 2024 | 307,000.00 |
| Mar 31, 2024 | 307,000.00 |
| Dec 31, 2023 | -664,000.00 |
| Dec 31, 2023 | -664,000.00 |